Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Hormone-sensitive Prostate Cancer: early-phase trial registry
4 of 6 indexed Metastatic Hormone-sensitive Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metastatic Hormone-sensitive Prostate Cancer: 6 US clinical trials tracked, 4 recruiting.
Metastatic Hormone-sensitive Prostate Cancer is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 2 of these trials.
Enrollment posture brief
Registry condition metastatic-hormone-sensitive-prostate-cancer
OPEN 4 | RECR 67% | LATE 1 | EARLY 4 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Metastatic Hormone-sensitive Prostate Cancer lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Hormone-sensitive Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Hormone-sensitive Prostate Cancer is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Hormone-sensitive Prostate Cancer research.
Bayer accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Metastatic Hormone-sensitive Prostate Cancer enrolment sits around 277 participants.
Median target enrolment is 277 among the 6 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Metastatic Hormone-sensitive Prostate Cancer research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Bayer
NCT07406282
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development
NCT05818683
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
Astellas Pharma Global Development
NCT07005154
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals
NCT06991556
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)
Merck Sharp & Dohme
NCT04191096
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.
Bayer
NCT05059236
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Hormone-sensitive Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Hormone-sensitive Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Hormone-sensitive Prostate Cancer page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Metastatic Hormone-sensitive Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bayer sponsors the most Metastatic Hormone-sensitive Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Hormone-sensitive Prostate Cancer condition card totals 6 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.